Retina

New clinical trials reveal PER-001 as a groundbreaking treatment for glaucoma and diabetic retinopathy, showing significant vision improvements and safety.

Walkable communities could aid in reduction of type 2 diabetes.

A study reveals a genetic link between instant coffee consumption and increased risk of dry age-related macular degeneration, urging caution for high-risk individuals.

Incorporating peripheral OCTs into your practice provides valuable insights that may alter your clinical diagnosis.

CLARUS 700, the advanced retinal imaging system, captures 133 degrees in a single image and up to 267 degrees with multiple images.

deepeye TPS is designed to close the gap between real-world outcomes and trial data by reducing patient dropout.

The results of an investigation into iRORA identified a wide spectrum of fundus autofluorescence patterns that corresponded with iRORA lesions and that those patterns were associated with conversion to cRORA over time.

Susvimo is the first and only FDA-approved, continuous delivery treatment shown to maintain vision in people with DR with just one refill every 9 months

New research reveals how low blood sugar can damage the retina in diabetes, highlighting potential treatments targeting specific proteins to prevent vision loss.

DREAM is an acronym for deep imaging depth, rapid sweeping speed, extensive scan range, accurate results, and multimodal imaging capabilities.

In total, 613,690 images used for screening were included in the study.

The recent study details the diagnostic value of a multimodal model utilizing both types of biomarkers when compared with unimodal models.

The system was taught quality standards by being fed more than 1400 images from different parts of the retina taken by adaptive-optics ophthalmoscopy.

The drug was previously approved for high blood pressure in 1955.

Topline results from the MAGNIFY phase 2 clinical trial of oral zervimesine show 28.6% slower geographic atrophy lesion growth compared with placebo.

Boehringer Ingelheim announced that the phase 2 clinical studies will investigate a potential first-in-class oral compound and a highly specific antibody fragment for geographic atrophy.

With the acquisition, Topcon Healthcare also assumes RetInSight’s AI algorithms that analyze retinal images to detect and monitor disease.

The company said it will be available on the US market for use in clinics and healthcare institutions.

The optimal triple-carotenoid supports daily eye health with lutein, zeaxanthin, and meso-zeaxanthin, according to the company.

The starry faculty has a galaxy of symposia planned for May 4, 2025.

The FDA did not agree with a supplemental Biologics License Application for the addition of extended dosing intervals of up to 24 weeks across currently-approved indications.

The supplemental BLA seeks approval for Eylea HD for both the treatment of macular edema following retinal vein occlusion and for broadening the dosing schedule to include every-4-week dosing across approved indications.

Good safety profile and “meaningful improvement” in vision in patient with Leber congenital amaurosis.

A Prescription Drug User Fee Act (PDUFA) goal date of August 27, 2025, was set by the organization.

Methylphenidate is a central nervous system stimulant that is used to treat ADHD, a very common diagnosis in children in the US.

Management strategies for patients with ocular syphilis primarily involve antibiotic treatment achieved using high-dose intravenous or intramuscular penicillin.

The decision to discontinue the trials comes shortly after the announcement that COAST missed its primary endpoint.

CRU Cofounder John Gelles, OD, gives his first impressions on how the conference is going thus far in Napa, California.